Global Oncology Market Shares and CAGRs of the Top 20 Pharma Companies Overview and Forecast Period 2023
orbisresearch.com added latest 31 pages report “Global Oncology Market to 2023-Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors” in its store.
Dallas, United States – July 20, 2017 /MarketersMedia/ —
In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.
Browse the complete report @ http://www.orbisresearch.com/reports/index/global-oncology-market-to-2023-robust-growth-driven-by-rising-prevalence-and-increased-uptake-of-immune-checkpoint-inhibitors
A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.
There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.
Scope
Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications?
How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
What proportion of the key players’ revenues will be attributable to oncology products?
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/357983
Reasons to buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals
Buy a report @ http://www.orbisresearch.com/contact/purchase/357983
List of Tables
Table 1: Oncology, Global, Symptoms of Key Indication Cancers, 2017 12
Table 2: Complications Associated with Breast, Colorectal, Lung, Prostate and Hematological Cancers 16
Table 3: Oncology, Global, Epidemiology of Key Indication Cancers, 2017 17
Table 4: Oncology Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017 22
Table 5: Oncology Market, US, Colorectal Cancer Stage and Survival Rates (%), 2017 23
Table 6: Oncology Market, US, Lung Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017 24
Table 7: Oncology, US, Prostate Cancer Stage at Diagnosis and Five-Year Relative Survival (%), 2017 24
Table 8: Optimal and Actual Chemotherapy Usage Rates, 2010 28
Table 9: Oncology Therapeutics Market, Global, Approved Indications for Rituxan, 2017 32
Table 10: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2017 34
Table 11: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2017 36
Table 12: Oncology Therapeutics Market, Global, Approved Indications for Revlimid, 2017 38
Table 13: Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2017 40
Table 14: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2017 41
Table 15: Oncology Therapeutics Market, Global, Approved Indications for Gleevec, 2017 43
Table 16: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2017 45
Table 17: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2017 46
Table 18: Oncology, Global, Market Size ($bn), 2016-2023 (Part 1) 87
Table 19: Oncology, Global, Market Size ($bn), 2016-2023 (Part 2) 94
Table 20: Oncology, Global, Usage of Generics Across Key Indications, 2017 102
Table 21: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2016-2023 112
Table 22: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017 131
Table 23: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017 149
Table 24: Oncology, Global, All Pipeline Products, 2017 163
Table 25: Abbreviations 417
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +912064101019
For more information, please visit http://www.orbisresearch.com/reports/index/global-oncology-market-to-2023-robust-growth-driven-by-rising-prevalence-and-increased-uptake-of-immune-checkpoint-inhibitors
Source: MarketersMedia
Release ID: 219733
Copyright © 1999-2013 SproutNews.com
